ArticleThrombosis journal2026
Hypofibrinogenemia caused by a heterozygous variant in the FGA gene: a case report.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHereditary Fibrinogen Disorders (HFDs) are conventionally classified as quantitative (type I) or qualitative (type II) deficiencies based on the plasma concentration. Quantitative deficiencies include afibrinogenemia/severe hypofibrinogenemia and hypofibrinogenemia, while qualitative deficiencies comprise dysfibrinogenemia and hypodysfibrinogenemia.
objectiveTo identify the molecular pathogenesis of hypofibrinogenemia in a pregnant patient and her family, and explore the clinical characteristics and peripartum management strategy of this disease.
methodsWe described the clinical data and genetic findings of a 28-year-old pregnant woman and her mother with hypofibrinogenemia. Sanger sequencing was used to verify the heterozygous variant c.1517del (exon 5) of the FGA gene (NM_021871.4). Relevant published literatures were analyzed to summarize the research progress and clinical implications of this variant.
resultsWe identified a novel pathogenic FGA c.1517del variant in a Chinese family with hereditary hypofibrinogenemia. The proband presented with decreased fibrinogen activity (1.6 g/L) and antigen level (1.7 g/L), with an activity/antigen ratio of 0.94; her mother showed similar laboratory abnormalities. The patient received 1.5 g intravenous fibrinogen before neuraxial anesthesia-assisted lower-segment cesarean section. A 3.53 kg female neonate was delivered smoothly without obvious intraoperative hemorrhage.
conclusionThe diagnosis of HFDs relies on combined detection of fibrinogen function, antigen level and genetic analysis. Genetic screening facilitates clinical diagnosis and genetic counseling. For pregnant patients with hypofibrinogenemia in late gestation, preoperative fibrinogen supplementation can effectively correct coagulation defects and ensure safe delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.